pharm edaily

Olympus Korea successfully concluded its launch symposium sharing insights on the clinical efficacy and applications of iTind a minimally invasive solution for treating benign prostatic hyperplasia (BPH).

iTind. (Image=Olympus Korea)

On the 9th Olympus Korea hosted the symposium for urologists nationwide to present clinical outcomes and practical uses of iTind which was launched domestically in March.

iTind is a temporary implantable medical device made from nitinol an alloy of titanium and nickel designed to relieve lower urinary tract symptoms caused by BPH. It offers a new minimally invasive treatment option that requires no incision can be performed under local anesthesia, and leaves no permanent implant in the body.

The symposium, held to mark iTind’s introduction into local clinics, aimed to share its clinical utility and real world application experiences with domestic medical professionals. The event consisted of three sessions product introduction clinical experience presentations and a discussion Q&A segment.

In the product introduction session, speakers highlighted iTind’s structural features. The device is inserted into the prostatic urethra in a folded state, where it gradually expands to gently exert pressure, reshaping the prostatic urethra and bladder neck.

The device remains in place for 5~7 days during which it gently remodels the tissue to improve urinary symptoms after which it is removed in a simple procedure. Most patients can return to daily activities within one to two days post procedure. The treatment takes about 30 minutes under local anesthesia or mild sedation and has a low risk of side effects.

The clinical experience session chaired by Dr. Cho Jeong ho of Goldman Urology Clinic, featured presentations by Dr. Lee Jang- ee (Incheon Himchan General Hospital), Dr. Lee Joong ho (Pohang Semyeong Christian Hospital), Dr. Han Ji yeon (Kangdong Sacred Heart Hospital), and Dr. Ahn Ji hoon (Mokpo Medical Center). They shared vivid case studies and firsthand experiences from their clinical practices.

In the final discussion and Q&A segment, participants exchanged insights on key factors behind high patient satisfaction, characteristics of suitable candidates for the procedure, and effective communication strategies with patients before and after treatment offering practical guidance for clinical adoption.

Kim Jung soo Executive Director of Olympus Korea said “This symposium was a meaningful occasion to commemorate iTind’s domestic launch and allow medical professionals to share their procedural experiences and know-how. We expect more clinicians will consider minimally invasive treatment options like iTind in real world practice.”

He added “Olympus Korea will continue to provide valuable information to healthcare professionals in urology and contribute to improving patient care.”